Clinical and biochemical presentation of polycystic ovary syndrome in women between the ages of 20 and 40
|
|
- Verity Green
- 6 years ago
- Views:
Transcription
1 Human Reproduction, Vol.26, No.12 pp , 2011 Advanced Access publication on September 16, 2011 doi: /humrep/der302 ORIGINAL ARTICLE Reproductive endocrinology Clinical and biochemical presentation of polycystic ovary syndrome in women between the ages of 20 and 40 So-Jung Liang 1,, Chun-Sen Hsu 1,, Chii-Ruey Tzeng 2, Chi-Huang Chen 2, and Ming-I Hsu 1, * 1 Department of Obstetrics and Gynecology, Wan Fang Hospital, Taipei Medical University, Taiwan No.111, Sec. 3, Xinglong Road, Taipei 11696, Taiwan 2 Department of Obstetrics and Gynecology, Taipei Medical University Hospital, Taipei Medical University, Taipei, Taiwan *Correspondence address. Tel: ; Fax: ; hsumingi@yahoo.com.tw Submitted on April 13, 2011; resubmitted on August 8, 2011; accepted on August 12, 2011 background: The clinical features and metabolic complications of polycystic ovary syndrome (PCOS) may change with age. This study was designed to investigate the clinical and biochemical characteristics of PCOS patients between the ages of 20 and 40. methods: The study included 781 Taiwanese women, of whom 453 were diagnosed with PCOS and 328 were non-pcos controls. Anthroponmetric components, androgens, endocrine, insulin resistance, and metabolic components were measured and correlated with age. Above parameters were compared between younger and elder women with PCOS. results: Age had significant negative correlations with androgens (total testosterone and dehydroepiandrosterone sulfate), the modified Ferriman Gallwey score and the prevalence of acne and hirsutism. Age had significant positive correlations with fasting glucose, cholesterol, triglycerides and low-density lipoprotein. The 453 women who fulfilled diagnostic criteria for PCOS were classified by age into two groups: Group A (20 29 years old, n ¼ 294) and Group B (30 40 years old, n ¼ 159). Group A had significantly higher total testosterone levels than Group B. Group B had higher fasting insulin and glucose levels, triglycerides, body mass index and waist measurements and a higher incidence of obesity than Group A. The average ovarian volume was not significantly different among the two groups. conclusions: Increased age is accompanied by a decrease in the prevalence of both clinical and biochemical hyperandrogenism in women. Hyperandrogenism is the important factor for young women with PCOS; however, abdominal obesity and certain metabolic disturbances became major concerns for older women with PCOS. Key words: polycystic ovary syndrome / age / hyperandrogenism / metabolic syndrome Introduction Polycystic ovary syndrome (PCOS) is the most common endocrine disorder of reproductive-age women, affecting an estimated 9 18% of all women in this age group, depending on the diagnostic criteria applied (March et al., 2010). PCOS is considered to be a polygenic trait, and clinical features of this disorder may change with age, beginning in adolescence and ending with menopause (Pasquali and Grambineri, 2006a). Investigating PCOS in women of various ages is crucial because it is now believed to increase metabolic and cardiovascular risk and these risks probably depend on age (Cheung et al., 2008). According to the 2003 Rotterdam criteria, a PCOS diagnosis can be reached when at least two of the following three criteria are met: hyperandrogenism and/or hyperandrogenemia (HA); oligomenorrhea or amenorrhea or anovulation (Oligo-An); and polycystic ovary morphology (PCOM; Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, 2004). However, the clinical and biochemical presentation of PCOS may change over time in women of reproductive age (Pasquali and Grambineri, 2006b). Oligomenorrhea may be an early symptom of PCOS, especially in overweight girls with hirsutism or acne (Mastorakos et al., 2006). Hyperandrogenism partially resolves before menopause in women with PCOS (Winters et al., 2000). Ovarian volume and the number of follicles decrease with age in women with PCOS (Alsamarai et al., 2009). Furthermore, aging may also be associated with a defect in insulin action (Rowe et al., 1983). Therefore, the clinical features and metabolic consequences of PCOS may change with age (Rodríguez-Morán and Guerrero-Romero, 2003), and these age-related changes may affect These authors contributed equally to this work. & The Author Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For Permissions, please journals.permissions@oup.com
2 3444 Liang et al. the observed incidence of PCOS (Bili et al., 2001). Unfortunately, there have been few reports examining the differences in the phenotype and clinical presentation of PCOS based on age (Pasquali and Grambineri, 2006a). The best way to study the aging process in women with PCOS is to perform a longitudinal study with the same subjects, but it is difficult to follow such patients for more than 20 years without introducing study bias. Therefore, we attempted to address the issue by performing a cross-sectional study to evaluate the clinical and biochemical characteristics of women, of different ages, who were diagnosed with PCOS. Materials and Methods This study was approved by the Institutional Review Board of the Wan Fang Medical Center at Taipei Medical University, Taipei, Taiwan. We retrospectively reviewed the medical records of female patients who visited the Reproductive Endocrinology Clinic at the Wan Fang Medical Center at Taipei Medical University from 1 April 2004 to 31 December The following subjects were excluded from the study: (i) women who had been diagnosed with other etiologies that should be excluded when establishing a PCOS diagnosis, such as hyperprolactinemia, hypogonadotropic hypogonadism, premature ovarian failure, congenital adrenal hyperplasia, androgen-secreting tumors, Cushing s syndrome, disorders of the uterus (e.g. Asherman s syndrome and Mullerian agenesis) and chromosomal anomalies (e.g. Turner s syndrome); (ii) women who were,20 or.40 years of age; (iii) women who experienced menarche,3 years prior to the start of the study or who had Day 3 FSH.15 miu/ml; (iv) women with inadequate clinical/biochemical records and (v) women who had had ovarian cysts or ovarian tumors in an ultrasonographic examination. After these exclusions, a total of 781 subjects were enrolled in the study. The subject s medical histories included a detailed menstrual history and data on body weight, height, hirsutism and the presence or the absence of clinical acne. Additionally, the levels of serum FSH, LH, prolactin, total testosterone, fasting insulin and fasting glucose were available. Waist girth was defined as the middle circumference between the iliac crest and the lateral costal margin. Hip circumference was defined as the largest measurement over the buttocks. The waist-to-hip ratio was defined as waist girth/hip girth. Body mass index (BMI) was defined as body weight in kilograms divided by body height in meters squared (kg/m 2 ). Obesity was defined as BMI 25 kg/m 2, according to the Asia-Pacific definition. The number of menstrual cycles in the previous 12 months was recorded. An ultrasound examination of the pelvis, preferably transvaginal, was performed to detect polycystic ovaries. The protocol for evaluating PCOS patients at our clinics was expanded in 1 June After this time, the following data were also available: (i) serum androgens, including androstenedione, dehydroepiandrosterone sulfate (DHEA-S), 17-a-OH progesterone and the free androgen index; (ii) the 2-h oral glucose tolerance test and glucose sex hormone-binding globulin (SHBG) levels; (iii) lipid profiles, including total cholesterol, triglycerides, highdensity lipoprotein (HDL) and low-density lipoprotein (LDL) and (iv) liver function and inflammatory markers, including glutamic oxaloacetic transaminase, glutamic pyruvic transaminase and high-sensitivity C-reactive protein. Therefore, 283 of 781 cases had this additional information. The serum FSH, LH and prolactin were measured using enzyme immunoassay (AxSym System, Abbott Laboratories, IL, USA); serum total testosterone, DHEA-S, 17-a-OH progesterone and androstenedione concentrations were measured by radioimmunoassay (Diagnostic Systems Laboratories, Webster, TX, USA); SHBG was measured using an electrochemiluminescence immunoassay (Roche Diagnostics, Indianapolis, IN, USA); the fasting insulin concentrations were measured by radioimmunoassay (Siemens Medical Solutions Diagnostics, Los Angeles, CA, USA) and the fasting glucose was measured using the Beckman Coulter Synchron LX (Fullerton, CA, USA). Hirsutism was defined as a modified Ferriman Gallwey (mf-g) score of 6. The patients suspected of clinical androgen excess showed manifestations of hirsutism and/or acne. Biochemical HA was defined as total serum testosterone of 2.78 mmol/l (0.80 ng/ml, 1 ng/ml ¼ 3.47 mmol/l). The study population Women with and without PCOS were included in this study. PCOS was diagnosed according to the 2003 Rotterdam criteria. The definitions of Oligo-An, HA and PCOM have been described in detail previously (Hsu et al., 2009). The eventual study population consisted of a total of 781 women (average age and range years old), which included 453 women with PCOS ( , years old) and 328 women without PCOS (average age , years old). Overall, 283 of the 781 cases were investigated after 1 June 2009, and additional information was obtained for this subgroup. We further classified the 453 women with PCOS into two subgroups, Group A consisted of women in their 20s (n ¼ 294, , years old), and Group B consisted of women of years old (n ¼ 159, ). Of the 453 subjects with PCOS, 145 were recruited after 1 June Of these cases, 85 were in Group A, and 60 were in Group B. The insulin sensitivity index was evaluated by the homeostasis model assessment insulin resistance (HOMA-IR) index using the following formula HOMA IR = Fasting insulin (mu/ml) Fasting glucose (mg/dl). 405 Metabolic syndrome has been defined as the presence of at least three of the following criteria, according to the third report of the National Cholesterol Education Program-Adult Treatment Panel III (ATP-III): abdominal obesity (a waist circumference.80 cm in women); serum TG 150 mg/dl or taking any medication for hypertriglyceridemia; serum HDL, 50 or taking any medication to increase the HDL level; BP 130 or 85 mmhg or taking any medication for hypertension; and fasting blood glucose 100 mg/dl or taking any medication for hyperglycemia. Statistical analysis SPSS 13.0 for Windows (SPSS, Inc., Chicago, IL, USA) was used for statistical analysis. We evaluated the correlation between age and PCOSrelated parameters using Pearson s correlation coefficients with a twotailed significance test; the results appear in Tables I and II. In Tables III and IV, the data are presented as the mean + SD. We used the x 2 and Fisher s exact tests to compare the categorical variables and an ANOVA model to compare the continuous variables in Tables III and IV. The means of more than two groups were compared using with the F-test and Dunnett s test with unequal variances for post hoc comparison. The difference between the groups were considered significant if the P-value was,0.05. Results Tables I and II show the correlation between ages and the PCOSrelated parameters for all of the study subjects. With all 781 of the study subjects included, Table I shows that age was negatively correlated with the total testosterone level (r ¼ , P, 0.001), acme, hirsutism and mf-g score (r ¼ , P, 0.001) and positively correlated with BMI, waist measurement, the fasting glucose
3 Clinical and biochemical presentation 3445 Table I The correlations between age and the clinical and biochemical parameters of PCOS (n 5 781). Total (n 5 781)... PCOS (n 5 453)... Non-PCOS (n 5 328)... Correlation P-value Correlation P-value Correlation P-value BMI * * Waist * <0.001*** Number of menstrual cycle per years * Average ovarian volume Total testosterone <0.001*** ** Acne <0.001*** * <0.001*** Hirsutism <0.001*** * <0.001*** mf-g score <0.001*** ** <0.001*** Fasting insulin Fasting glucose <0.001*** <0.001*** <0.001*** HOMA-IR * HOMA-IR, homeostasis model assessment insulin resistance index. Bold values indicate the parameter s significant correlation with age. **P, ***P, Table II The correlations between age and additional clinical and biochemical parameters of PCOS (n 5 283, data obtained after 1 June 2009). Total (n 5 283)... PCOS (n 5 145)... Non-PCOS (n 5 138)... Correlation P-value Correlation P-value Correlation P-value Androstenedione DHEA-S <0.001*** ** * 17-a-OH progesterone Cholesterol <0.001** * <0.001*** Triglyceride * * <0.001*** HDL LDL * * 2-h Glucose ** * * SHBG Anti-Müllerian hormone ** * Follicles number per ovary DHEA-S, dehydroepiandrosterone sulfate; HDL, high-density lipoprotein; LDL, low-density lipoprotein; SHBG, sex hormone-binding globulin. Bold values indicate the parameter s significant correlation with age. **P, ***P, level (r ¼ 0.205, P, 0.001) and the number of menstrual cycles per year. Table II shows that age was negatively correlated with DHEA-S (r ¼ , P, 0.001) and anti-müllerian hormone (r ¼ , P ¼ 0.019) in the 283-case subgroup (of the 781 study subjects) and positively correlated with cholesterol (r ¼ 0.221, P, 0.001), triglycerides (r ¼ 0.139, P ¼ 0.007) and LDL (r ¼ 0.158, P ¼ 0.007). The prevalence of acne, hirsutism, the mf-g score and serum DHEA-S level were negatively correlated with age in both the PCOS and the non-pcos women. The cholesterol, triglyceride and fasting glucose levels were significantly positively correlated with age in both the PCOS and the non-pcos women. In Tables III and IV, all of the women with PCOS are classified into two groups according their ages: Group A (n ¼ 294, years old) and Group B (n ¼ 159, years old). Of the three PCOS criteria, PCOM was the most predominant characteristic of the women with PCOS. For the women who fulfilled the PCOS diagnostic criteria,
4 3446 Liang et al. Table III A comparison of clinical characteristics of the women with PCOS in the and years old groups. Total Group A (20 29 years old) Group B (30 40 years old) P-value (n 5 453) (n 5 294) (n 5 159) (A versus B) Age (years) Menarche (years) PCOS criteria Oligo- and/or anovulation (%) Clinical and/or biochemical hyperandrogenism (%) PCOM (%) Anthroponmetric components BMI (kg/m 2 ) ** Weight (kg) * Height (cm) * Waist (cm) <0.001*** Hip (cm) * Waist-to-hip ratio <0.001*** Obesity (%) * Androgens Biochemical HA (%) Acne (%) Hirsutism (%) mf-g score Testosterone (mmol/l) * Endocrine Prolactin (miu/ml) LH (miu/ml) FSH (miu/ml) LH-to-FSH ratio Insulin resistance Fasting Insulin (miu/ml) * Fasting glucose (mg/dl) ** HOMA-IR Average ovarian volume (ml) Number of menstrual cycles per year Data are either mean + SD or percentage. HOMA-IR, homeostasis model assessment insulin resistance index. Bold values indicate the parameter s significant difference between two groups. **P, ***P, Group A had a significantly higher total testosterone levels than Group B. Group B had higher levels of some metabolic disturbances (elevated fasting glucose and insulin levels, BMI, waist measurement and triglycerides and a higher incidence of obesity) than Group A. The serum LH, FSH levels and average ovarian volume were not significantly different among two groups. Discussion Clinical and biochemical androgen excesses are major characteristics of women with PCOS. An age-related decrease in androgen secretion occurs in women with PCOS, as it does in normal women. Ovarian steroid secretion capacity starts to decline as early as age 30 (Piltonen et al., 2004), and hyperandrogenism partially resolves before menopause in women with PCOS (Winters et al., 2000). The presentation of androgen excess was highly age-dependent both in the current study and in previous reports. Bili et al. (2001) studied 472 oligomenorrheic and amenorrheic infertile patients and found that age was inversely correlated with testosterone, androstenedione and dehydroepiandrosterone. Morán et al. (1999) studied 145 hyperandrogenic women and reported a negative association between DHEA-S levels and age.
5 Clinical and biochemical presentation 3447 Table IV A comparison of addition clinical characteristics of the women with PCOS in the and years old groups (n 5 145, data obtained after 1 June 2009). Total Group A (20 29 years old) Group B (30 40 years old) P-value (n 5 145) (n 5 85) (n 5 60) (A versus B) Age (years) Androgens Androstenedione (ng/dl) DHEA-S (ng/dl) * 17-OH PRG (ng/dl) SHBG (nmol/l) Oral glucose tolerance test 2-h glucose (mg/dl) Lipids Cholesterol (mg/dl) Triglyceride (mg/dl) * HDL (mg/dl) LDL (mg/dl) Inflammatiom hscrp (mg/dl) Liver enzyme GOT (IU/l) GPT (IU/l) Blood pressure Systolic pressure (mmhg) Diastolic pressure (mmhg) Metabolism syndrome Metabolic syndrome (%) Hypertension (%) HDL, 50 mg/dl (%) * Triglyceride. 150 mg/dl (%) Waist. 80 cm (%) * Data are either mean + SD or percentage. DHEA-S, dehydroepiandrosterone sulfate; 17-OH PRG, 17-a-OH progesterone; HDL, high-density lipoprotein; LDL, low-density lipoprotein; SHBG, sex hormone-binding globulin; GOT, glutamic oxaloacetic transaminase; GPT, glutamic pyruvic transaminase; hscrp, high-sensitivity C-reactive protein. Bold values indicate the parameter s significant difference between two groups. Winters et al. (2000) studied 84 women with PCOS and found that levels of total testosterone and non-shbg-bound testosterone were lower in older women with PCOS. Our study found that serum androgen markers (total testosterone and DHEA-S) were significantly negatively correlated with age. Furthermore, we found the prevalence of acne and hirsutism, and the mf-g score had significant negative associations with age in the women with and without PCOS. Accordingly, the prevalence of both clinical hyperandrogenism and biochemical HA should decrease as women age. Some studies have found that morphological ultrasonographic features consistent with polycystic ovaries are common in postmenopausal women and that these features are associated with higher than normal testosterone levels and metabolic alterations (Birdsall and Farquhar, 1996). Our results did not indicate any significant correlation between age and ovarian volume. However, the Pavlik et al. (2000) study of age and ovarian volume demonstrated a stable ovarian volume to age 35, the greatest decline between 35 and 55 years old and a minor decline after age 55. In normally ovulating women, ovarian volume decreases with age, with measurable decreases across each decade of reproductive life starting at age (Pavlik et al., 2000; Oppermann et al., 2003). Furthermore, the decrease in ovarian volume is less pronounced in the women with PCOS than in the controls (Alsamarai et al., 2009). Our subjects consisted of 781 cases with average age of 28.6 (all of whom were,40 years old), and the ovarian volumes were relatively stable at this stage. Previous studies have suggested that menstrual cycles may become regular with age in women with PCOS (Birdsall and Farquhar, 1996; Elting et al., 2003). Our results also showed that the number of menstrual cycles per year was positively correlated with age. These results are consistent with previous reports.
6 3448 Liang et al. As described above, age can influence the status of women diagnosed with PCOS. Women diagnosed with PCOS, by 2003 Rotterdam criteria may have different phenotypes depending on age. In patients with PCOS, a PCOM was the most prevalent criterion for women age 20. While the prevalence of clinical and/or biochemical hyperandrogenism significantly decreases with age and the severity of menstrual disturbances may improve after age 20, ovarian volume and ovarian morphology seem to be relatively stable for women younger than 35 (Pavlik et al., 2000). Therefore, a PCOM became the prevalent diagnostic criterion for PCOS in women over 20 years old. Age is also an important risk factor for developing metabolic disorders and cardiovascular events. In the correlation analysis, we found that advanced age was associated with increased cholesterol, triglyceride and LDL levels. Furthermore, aging may also be associated with a defect in insulin action that is manifested by decreased whole-body tissue sensitivity to insulin without a change in tissue responsiveness (Rowe et al., 1983). The significant positive correlation between fasting glucose levels and age in the women with and without PCOS may reflect a glucose intolerance that develops as part of the aging process. In elderly subjects, the severity of carbohydrate intolerance correlates directly with the degree of peripheral insulin resistance (Fink et al., 1983). Our data showed that age positively correlated with BMI in women with PCOS, which was not true in the non-pcos groups. Furthermore, the PCOS women in Group A (20 29 years old) and Group B (30 40 years old) had a similar prevalence of hyperandrogenism, but Group B had significantly higher BMI scores and incidence of obesity than Group A. This finding is an interesting phenomenon. It is known that as age increases, serum total testosterone levels decrease. Furthermore, serum testosterone was strongly positively correlated with BMI in our study and previous reports (Pasquali et al., 2006). If an older group fulfills the set diagnostic criteria for PCOS, they may present with more obesity and higher BMI scores than a younger age group. In comparison to younger women with PCOS, therefore, older PCOS patients should face both age- and BMI-related increases in risk of insulin resistance and metabolic disturbance. For women of age 30, the negative impact of PCOS on health is clear. Compared with younger women, we found that PCOS patients of age 30 had higher fasting glucose levels, cholesterol, triglycerides, BMI and waist measurements consistent with Gülekli s suggestion that PCOS patients are prone to gain weight as they get older (Gülekli et al., 1993). This result implies that the association between abdominal obesity and metabolic disturbance in women with PCOS becomes clear later in life. Adolescent oligomenorrhea may spontaneously resolve and may modify the diagnosis. Diagnosing PCOS during adolescence using the Rotterdam criteria may not be appropriate (Carmina et al., 2010). Therefore, our study excluded women,20 years old. We evaluated the clinical and biochemical characteristics of the women with PCOS according to the age group; we also analyzed the correlation between age and PCOS-related markers. The results of our study suggested that some of the diagnostic criteria for PCOS might be modified when applied to different age groups. In conclusion, a PCOM was the most common PCOS diagnostic criteria in women over age 20. The severity of clinical and biochemical hyperandrogenism decreased with age. But after age 29, abdominal obesity and certain metabolic disturbances became more prevalent in women with PCOS. Authors roles S.-J.L. wrote this revision. C.-S.H. wrote the manuscript. C.-R.T. provided the concept. C.-H.C. analyzed the data. M.-I.H. designed and approved the manuscript. Funding This work was supported by a grant from the National Science Council (NSC B MY3) (2-3) and by Taipei Medical University and Wan Fang Hospital (99-TMU-WFH-03-01). References Alsamarai S, Adams JM, Murphy MK, Post MD, Hayden DL, Hall JE, Welt CK. Criteria for polycystic ovarian morphology in polycystic ovary syndrome as a function of age. J Clin Endocrinol Metab 2009; 94: Bili H, Laven J, Imani B, Eijkemans MJ, Fauser BC. Age-related differences in features associated with polycystic ovary syndrome in normogonadotrophic oligo-amenorrhoeic infertile women of reproductive years. Eur J Endocrinol 2001;145: Birdsall MA, Farquhar CM. Polycystic ovaries in pre and post-menopausal women. Clin Endocrinol (Oxf) 1996;44: Carmina E, Oberfield SE, Lobo RA. The diagnosis of polycystic ovary syndrome in adolescents. Am J Obstet Gynecol 2010; 203:201.e1 201.e5. Cheung LP, Ma RC, Lam PM, Lok IH, Haines CJ, So WY, Tong PC, Cockram CS, Chow CC, Goggins WB. Cardiovascular risks and metabolic syndrome in Hong Kong Chinese women with polycystic ovary syndrome. Hum Reprod 2008;23: Elting MW, Kwee J, Korsen TJ, Rekers-Mombarg LT, Schoemaker J. Aging women with polycystic ovary syndrome who achieve regular menstrual cycles have a smaller follicle cohort than those who continue to have irregular cycles. Fertil Steril 2003;79: Fink RI, Kolterman OG, Griffin J, Olefsky JM. Mechanisms of insulin resistance in aging. J Clin Invest 1983;71: Gülekli B, Turhan NO, Senöz S, Kükner S, Oral H, Gökmen O. Endocrinological, ultrasonographic and clinical findings in adolescent and adult polycystic ovary patients: a comparative study. Gynecol Endocrinol 1993;7: Hsu MI, Liou TH, Liang SJ, Su HW, Wu CH, Hsu CS. Inappropriate gonadotropin secretion in polycystic ovary syndrome. Fertil Steril 2009; 91: March WA, Moore VM, Willson KJ, Phillips DI, Norman RJ, Davies MJ. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod 2010; 25: Mastorakos G, Lambrinoudaki I, Creatsas G. Polycystic ovary syndrome in adolescents: current and future treatment options. Paediatr Drugs 2006; 8: Morán C, Knochenhauer E, Boots LR, Azziz R. Adrenal androgen excess in hyperandrogenism: relation to age and body mass. Fertil Steril 1999; 71: Oppermann K, Fuchs SC, Spritzer PM. Ovarian volume in pre- and perimenopausal women: a population-based study. Menopause 2003; 10: Pasquali R, Gambineri A. Polycystic ovary syndrome: a multifaceted disease from adolescence to adult age. Ann N Y Acad Sci 2006; 1092:
7 Clinical and biochemical presentation 3449 Pasquali R, Gambineri A, Pagotto U. The impact of obesity on reproduction in women with polycystic ovary syndrome. BJOG 2006; 113: Pavlik EJ, DePriest PD, Gallion HH, Ueland FR, Reedy MB, Kryscio RJ, van Nagell JR Jr. Ovarian volume related to age. Gynecol Oncol 2000; 77: Piltonen T, Koivunen R, Perheentupa A, Morin-Papunen L, Ruokonen A, Tapanainen JS. Ovarian age-related responsiveness to human chorionic gonadotropin in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004;89: Rodríguez-Morán M,Guerrero-Romero F.Insulin resistance is independently related to age in Mexican women. J Endocrinol Invest 2003;26: Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81: Rowe JW, Minaker KL, Pallotta JA, Flier JS. Characterization of the insulin resistance of aging. J Clin Invest 1983;71: Winters SJ, Talbott E, Guzick DS, Zborowski J, McHugh KP. Serum testosterone levels decrease in middle age in women with the polycystic ovary syndrome. Fertil Steril 2000;73:
Antim ullerian hormone and polycystic ovary syndrome
Antim ullerian hormone and polycystic ovary syndrome Yi-Hui Lin, M.D., a Wan-Chun Chiu, Ph.D., c Chien-Hua Wu, Ph.D., b,e Chii-Ruey Tzeng, M.D., d Chun-Sen Hsu, M.D., a and Ming-I Hsu, M.D. a a Department
More informationMETABOLIC RISK MARKERS IN WOMEN WITH POLYCYSTIC OVARIAN MORPHOLOGY
Vuk Vrhovac University Clinic Dugi dol 4a, HR-10000 Zagreb, Croatia Original Research Article Received: February 18, 2010 Accepted: March 3, 2010 METABOLIC RISK MARKERS IN WOMEN WITH POLYCYSTIC OVARIAN
More informationROLE OF HORMONAL ASSAY IN DIAGNOSING PCOD DR GAANA SREENIVAS (JSS,MYSURU)
ROLE OF HORMONAL ASSAY IN DIAGNOSING PCOD DR GAANA SREENIVAS (JSS,MYSURU) In 1935, Stein and Leventhal described 7 women with bilateral enlarged PCO, amenorrhea or irregular menses, infertility and masculinizing
More informationPolycystic Ovary Syndrome HEATHER BURKS, MD OU PHYSICIANS REPRODUCTIVE MEDICINE SEPTEMBER 21, 2018
Polycystic Ovary Syndrome HEATHER BURKS, MD OU PHYSICIANS REPRODUCTIVE MEDICINE SEPTEMBER 21, 2018 Learning Objectives At the conclusion of this lecture, learners should: 1) Know the various diagnostic
More informationThe prevalence of polycystic ovary syndrome in Iranian women based on different diagnostic criteria
Prace oryginalne/original papers Endokrynologia Polska/Polish Journal of Endocrinology Tom/Volume 62; Numer/Number 3/2011 ISSN 0423 104X The prevalence of polycystic ovary syndrome in Iranian women based
More informationDetermining the insulin resistance rate in Polycystic Ovary Syndrome patients (PCOs)
Abstract: Determining the insulin resistance rate in Polycystic Ovary Syndrome patients (PCOs) Ashraf Olabi, Ghena Alqotini College of medicine, Aleppo University Hospital Obstetrics and Gynacology, Syria.
More informationClinical and endocrine characteristics of the main polycystic ovary syndrome phenotypes
POLYCYSTIC OVARY SYNDROME Clinical and endocrine characteristics of the main polycystic ovary syndrome phenotypes Ettore Guastella, M.D., a Rosa Alba Longo, M.D., b and Enrico Carmina, M.D. b a Department
More informationInvestigation of adrenal functions in patients with idiopathic hyperandrogenemia
European Journal of Endocrinology (26) 155 37 311 ISSN 84-4643 CLINICAL STUDY Investigation of adrenal functions in patients with idiopathic hyperandrogenemia Hulusi Atmaca, Fatih Tanriverdi 1, Kursad
More informationRotterdam Criteria 9/30/2017. A Changing Paradigm in PCOS. Polycystic Ovary Syndrome - Is the Cardiometabolic Risk Increased After Menopause?
Disclosure Polycystic Ovary Syndrome - Is the Cardiometabolic Risk Increased After Menopause? Fractyl laboratories, Inc Anuja Dokras, MD., Ph.D. Professor of Obstetrics and Gynecology Director PENN PCOS
More informationNitasha Garg 1 Harkiran Kaur Khaira. About the Author
https://doi.org/10.1007/s13224-017-1082-4 ORIGINAL ARTICLE A Comparative Study on Quantitative Assessment of Blood Flow and Vascularization in Polycystic Ovary Syndrome Patients and Normal Women Using
More informationWEIGHT CHANGE AND ANDROGEN LEVELS DURING CONTRACEPTIVE TREATMENT OF WOMEN AFFECTED BY POLYCYSTIC OVARY
ENDOCRINE REGULATIONS, VOL. 40, 119-123, 2006 119 WEIGHT CHANGE AND ANDROGEN LEVELS DURING CONTRACEPTIVE TREATMENT OF WOMEN AFFECTED BY POLYCYSTIC OVARY J. VRBIKOVA, K. DVORAKOVA, M. HILL, L. STARKA Institute
More informationClinical Study Hyperandrogenism Does Not Influence Metabolic Parameters in Adolescent Girls with PCOS
International Endocrinology Volume 2012, Article ID 434830, 5 pages doi:10.1155/2012/434830 Clinical Study Hyperandrogenism Does Not Influence Metabolic Parameters in Adolescent Girls with PCOS Kim Forrester-Dumont,
More informationX/06/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 91(1):2 6 Copyright 2006 by The Endocrine Society doi: /jc.
0021-972X/06/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 91(1):2 6 Printed in U.S.A. Copyright 2006 by The Endocrine Society doi: 10.1210/jc.2005-1457 EXTENSIVE CLINICAL EXPERIENCE Relative
More informationCan Sex hormone Binding Globulin Considered as a Predictor of Response to Pharmacological Treatment in Women with Polycystic Ovary Syndrome?
www.ijpm.in www.ijpm.ir Can Sex hormone Binding Globulin Considered as a Predictor of Response to Pharmacological Treatment in Women with Polycystic Ovary Syndrome? Ferdous Mehrabian, Maryam Afghahi Department
More informationCase Questions. Polycystic Ovarian Syndrome: Treatment Goals and Options. Differential Diagnosis of Hyperandrogenic Anovulation
Polycystic Ovarian Syndrome: Treatment Goals and Options Marc Cornier, MD Division of Endocrinology, Metabolism and Diabetes Colorado Center for Health and Wellness University of Colorado School of Medicine
More informationPrevalence of polycystic ovarian syndrome in the Buraimi region of Oman
Original Article Brunei Int Med J. 2012; 8 (5): 248-252 Prevalence of polycystic ovarian syndrome in the Buraimi region of Oman Usha VARGHESE 1 and Shaji VARUGHESE 2, 1 Department of Internal Medicine
More informationClinical Profile Polycystic Ovarian Syndrome Cases
ORIGINAL RESEARCH www.ijcmr.com - 100 Cases Himabindu Sangabathula 1, Neelima Varaganti 1 ABSTRACT Introduction: Polycystic ovary syndrome (PCOS) is most common endocrine disorders of reproductive age
More informationDr Stella Milsom. Endocrinologist Fertility Associates Auckland. 12:30-12:40 When Puberty is PCO
Dr Stella Milsom Endocrinologist Fertility Associates Auckland 12:30-12:40 When Puberty is PCO Puberty or Polycystic Ovary Syndrome? Stella Milsom Endocrinologist Auckland DHB, University of Auckland,
More information12/13/2017. Important references for PCOS. Polycystic Ovarian Syndrome (PCOS) for the Family Physician. 35 year old obese woman
Polycystic Ovarian Syndrome (PCOS) for the Family Physician Barbara S. Apgar MD, MS Professor or Family Medicine University of Michigan Ann Arbor, Michigan Important references for PCOS Endocrine Society
More informationWHY NEW DIAGNOSTIC CRITERIA FOR DIFFERENT PCOS PHENOTYPES ARE URGENTLY NEEDED
WHY NEW DIAGNOSTIC CRITERIA FOR DIFFERENT PCOS PHENOTYPES ARE URGENTLY NEEDED Ricardo Azziz, M.D., M.P.H., M.B.A. Chief Officer of Academic Health & Hospital Affairs State University of New York (SUNY)
More informationASSOCIATION OF INSULIN RESISTANCE AND SERUM 25 OH VITAMIN-D IN INDIAN WOMEN WITH POLYCYSTIC OVARY SYNDROME
RESEARCH ARTICLE ASSOCIATION OF INSULIN RESISTANCE AND SERUM 25 OH VITAMIN-D IN INDIAN WOMEN WITH POLYCYSTIC OVARY SYNDROME Amar Nagesh Kumar 1, Jupalle Nagaiah Naidu 2, Uppala Satyanarayana 3, Medabalmi
More informationS. AMH in PCOS Research Insights beyond a Diagnostic Marker
S. AMH in PCOS Research Insights beyond a Diagnostic Marker Dr. Anushree D. Patil, MD. DGO Scientist - D National Institute for Research in Reproductive Health (Indian Council of Medical Research) (Dr.
More informationOriginal Investigation. 94 Endocrine Oncology and Metabolism. Jovanovska et al
Original Investigation Sensitivity and specificity of anti-mülerian hormone in the diagnosis of polycystic ovary syndrome in a macedonian population of women of reproductive age: a cross-sectional study
More informationCan high serum anti-müllerian hormone levels predict the phenotypes of polycystic ovary syndrome (PCOS) and metabolic disturbances in PCOS patients?
ORIGINAL ARTICLE http://dx.doi.org/1.5653/cerm.213.4.3.135 pissn 2233-8233 eissn 2233-8241 Clin Exp Reprod Med 213;4(3):135-14 Can high serum anti-müllerian hormone levels predict the phenotypes of polycystic
More informationOverview of Reproductive Endocrinology
Overview of Reproductive Endocrinology I have no conflicts of interest to report. Maria Yialamas, MD Female Hypothalamic--Gonadal Axis 15 4 Hormone Secretion in the Normal Menstrual Cycle LH FSH E2, Progesterone,
More informationComparative study of metabolic profile of women presenting with polycystic ovary syndrome in relation to body mass index
International Journal of Reproduction, Contraception, Obstetrics and Gynecology Akshaya S et al. Int J Reprod Contracept Obstet Gynecol. 2016 Aug;5(8):2561-2565 www.ijrcog.org pissn 2320-1770 eissn 2320-1789
More informationWhat every dermatologist should know about Polycystic Ovary Syndrome (PCOS)
What every dermatologist should know about Polycystic Ovary Syndrome (PCOS) Kanade Shinkai, MD PhD University of California, San Francisco Associate Professor of Dermatology I have no conflicts of interest
More informationOvarian Volume in Korean Women with Polycystic Ovary Syndrome and Its Related Factors
pissn: 2288-6478, eissn: 2288-6761 Original Article Ovarian Volume in Korean Women with Polycystic Ovary Syndrome and Its Related Factors Young Shin Han 1, Ah Rha Lee 1, Hee Kyoung Song 1, Jeong In Choi
More informationMetformin Therapy Decreases Hyperandrogenism and Ovarian Volume in Women with Polycystic Ovary Syndrome
IJMS Vol 36, No 2, June 2011 Original Article Metformin Therapy Decreases Hyperandrogenism and Ovarian Volume in Women with Polycystic Ovary Syndrome Marzieh Farimani Sanoee 1, Nosrat Neghab 1, Soghra
More informationMetabolic syndrome in females with polycystic ovary syndrome and International Diabetes Federation criteria
doi:10.1111/j.1447-0756.2007.00685.x J. Obstet. Gynaecol. Res. Vol. 34, No. 1: 62 66, February 2008 Metabolic syndrome in females with polycystic ovary syndrome and International Diabetes Federation criteria
More informationPolycystic Ovary Syndrome (PCOS):
Polycystic Ovary Syndrome (PCOS): Current diagnosis and treatment Anatte E. Karmon, MD Disclosures- Anatte Karmon, MD No financial relationships to disclose 2 Objectives At the end of this presentation,
More informationClinical and biochemical characteristics of polycystic ovary syndrome in Korean women
Human Reproduction Vol.23, No.8 pp. 1924 1931, 2008 Advance Access publication on June 24, 2008 doi:10.1093/humrep/den239 Clinical and biochemical characteristics of polycystic ovary syndrome in Korean
More informationEuropean Journal of Endocrinology (2006) ISSN
European Journal of Endocrinology (2006) 154 141 145 ISSN 0804-4643 CLINICAL STUDY Metabolic syndrome in polycystic ovary syndrome (PCOS): lower prevalence in southern Italy than in the USA and the influence
More informationJMSCR Vol 05 Issue 05 Page May 2017
www.jmscr.igmpublication.org Impact Factor 5.84 Index Copernicus Value: 83.27 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v5i5.14 Hyperinsulinemia in Polycystic Ovary Syndrome
More informationClinical Manifestations of the Polycystic Ovary Syndrome at Menopausal Age
American Journal of Medicine and Medical Sciences 2019, 9(1): 35-39 DOI: 10.5923/j.ajmms.20190901.06 Clinical Manifestations of the Polycystic Ovary Syndrome at Menopausal Age Gafurova F. A. Assistant
More informationThe Relation between Diverse Phenotypes of PCOS with Clinical Manifestations, Anthropometric Indices and Metabolic Characteristics
ORIGINAL ARTICLE The Relation between Diverse Phenotypes of PCOS with Clinical Manifestations, Anthropometric Indices and Metabolic Characteristics Seyedeh Hajar Sharami 1, Zahra Abbasi Ranjbar 2, Forozan
More informationUniversity of Cape Town
P a g e 1 The Polycystic Ovary Syndrome a comparison of the presentation in adolescents compared to women aged 35 years and older attending the Gynaecological Endocrine clinic at Groote Schuur Hospital.
More informationPrevalence of Polycystic Ovarian Syndrome among urban adolescent girls and young women in Mumbai
Prevalence of Polycystic Ovarian Syndrome among urban adolescent girls and young women in Mumbai Principal Investigator Co- Investigators Consultant Collaborating Hospital Dr. Beena Joshi Dr. Srabani Mukherji
More informationPOLYCYSTIC OVARIAN SYNDROME Laura Tatpati, MD Reproductive Endocrinology and Infertility. Based on: ACOG No. 108 Oct 2009; reaffirmed 2015
POLYCYSTIC OVARIAN SYNDROME Laura Tatpati, MD Reproductive Endocrinology and Infertility Based on: ACOG No. 108 Oct 2009; reaffirmed 2015 NO DISCLOSURES PATIENT 26 years old presents with complaint of
More informationMetformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome
FERTILITY AND STERILITY VOL. 69, NO. 4, APRIL 1998 Copyright 1998 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Metformin therapy improves
More information3. Metformin therapy for PCOS
1. Introduction The key clinical features of polycystic ovary syndrome (PCOS) are hyperandrogenism (hirsutism, acne, alopecia) and menstrual irregularity with associated anovulatory infertility. 1 The
More informationDiagnostic Performance of Serum Total Testosterone for Japanese Patients with Polycystic Ovary Syndrome
Endocrine Journal 2007, 54 (2), 233 238 Diagnostic Performance of Serum Total Testosterone for Japanese Patients with Polycystic Ovary Syndrome TAKESHI IWASA, TOSHIYA MATSUZAKI, MASAHIRO MINAKUCHI, NAOKO
More informationPolycystic Ovary Syndrome
Polycystic Ovary Syndrome Definition: the diagnostic criteria Evidence of hyperandrogenism, biochemical &/or clinical (hirsutism, acne & male pattern baldness). Ovulatory dysfunction; amenorrhoea; oligomenorrhoea
More informationNew PCOS guidelines: What s relevant to general practice
New PCOS guidelines: What s relevant to general practice Dr Michael Costello Fertility Specialist IVF Australia UNSW Royal Hospital for Women Sydney How do we know if something is new? Louvre Museum, Paris
More informationPolycystic Ovarian Syndrome: Diagnosis, Preconceptional Management and Health Risks
Polycystic Ovarian Syndrome: Diagnosis, Preconceptional Management and Health Risks Kate D. Schoyer, M.D. May 6, 2016 Objectives To review how to make the diagnosis of Polycystic Ovarian Syndrome (PCOS)
More informationPCOS Awareness Symposium Atlanta September 24 th, Preventing Diabetes & Cardiovascular Disease in PCOS
PCOS Awareness Symposium Atlanta September 24 th, 2016 Preventing Diabetes & Cardiovascular Disease in PCOS Katherine Sherif, MD Professor & Vice Chair, Department of Medicine Director, Jefferson Women
More informationReceived: Accepted:
Received: 4.4.2011 Accepted: 11.6.2011 Original Article The prevalence of metabolic syndrome and insulin resistance according to the phenotypic subgroups of polycystic ovary syndrome in a representative
More information16 YEAR-OLD OBESE FEMALE WITH OLIGOMENORRHEA
16 YEAR-OLD OBESE FEMALE WITH OLIGOMENORRHEA Katie O Sullivan, MD Adult/Pediatric Endocrinology Fellow University of Chicago ENDORAMA Thursday, September 4th, 2014 Disclosures No financial interests. Will
More informationMetabolic Syndrome Among Infertile Women with Polycystic Ovary Syndrome
Med. J. Cairo Univ., Vol. 82, No. 2, September: 75-79, 2014 www.medicaljournalofcairouniversity.net Metabolic Syndrome Among Infertile Women with Polycystic Ovary Syndrome HANY AYASH, M.D.* and AMRO ABO
More informationFemale androgen profiles by MS for PCOS patients. CS Ho APCCMS 2010, Hong Kong 14 January 2010
Female androgen profiles by MS for PCOS patients CS Ho APCCMS 2010, Hong Kong 14 January 2010 873 women with increased serum androgens Androgen-secreting neoplasms 0.2% Classical CAH 0.6% Non-classical
More informationCase. 24 year old female presented to your office complaining of excess hair growth on her face and abdomen. Questions?
Hirsutism Case 24 year old female presented to your office complaining of excess hair growth on her face and abdomen Questions? Started around puberty with gradual progression Irregular menstrual cycle
More informationReproductive Health in Non Alcoolic Fatty Liver Disease (NAFLD)
Reproductive Health in Non Alcoolic Fatty Liver Disease (NAFLD) Pr Sophie Christin-Maitre Reproductive Endocrine Unit, Hôpital Saint-Antoine, AP-HP Université Pierre et Marie Curie INSERM U933 Paris, France
More informationThe excess in 2 5 mm follicles seen at ovarian ultrasonography is tightly associated to the follicular arrest of the polycystic ovary syndrome
Human Reproduction Vol.22, No.6 pp. 1562 1566, 2007 Advance Access publication on April 20, 2007 doi:10.1093/humrep/dem060 The excess in 2 5 mm follicles seen at ovarian ultrasonography is tightly associated
More informationPolycystic Ovary Syndrome
Polycystic Ovary Syndrome Kathleen Colleran, MD Professor of Medicine University of New Mexico HSC Presented for COMM-TC May 4, 2012 Objectives Understand the pathophysiology of PCOS Understand how to
More informationResearch Article Does Polycystic Ovary Syndrome Itself Have Additional Effect on Apelin Levels?
Obstetrics and Gynecology International, Article ID 536896, 4 pages http://dx.doi.org/10.1155/2014/536896 Research Article Does Polycystic Ovary Syndrome Itself Have Additional Effect on Apelin Levels?
More informationPolycystic Ovarian Syndrome: Diagnosis, Preconceptional Management and Health Risks. Kate D. Schoyer, M.D. May 6, 2016
Polycystic Ovarian Syndrome: Diagnosis, Preconceptional Management and Health Risks Kate D. Schoyer, M.D. May 6, 2016 Objectives To review how to make the diagnosis of Polycystic Ovarian Syndrome (PCOS)
More informationMetfornim and Pioglitazone in polycystic ovarian syndrome: A comparative study
Original Research Article Metfornim and Pioglitazone in polycystic ovarian syndrome: A comparative study Allanki Suneetha Devi 1, Jalem Anuradha 2* 1 Associate Professor, Department of Obstetrics and Gynecology,
More informationCORRELATION OF OBESITY, INSULIN RESISTANCE AND LIPID PROFILE IN WOMEN WITH PCOS IN KIMS HOSPITAL BANGALORE Shashikala H. Gowda 1, Mansi Dhingra 2
CORRELATION OF OBESITY, INSULIN RESISTANCE AND LIPID PROFILE IN WOMEN WITH PCOS IN KIMS HOSPITAL BANGALORE Shashikala H. Gowda 1, Mansi Dhingra 2 HOW TO CITE THIS ARTICLE: Shashikala H. Gowda, Mansi Dhingra.
More informationPolycystic Ovarian Syndrome. Heidi Hallonquist, MD Concord Hospital Concord Obstetrics and Gynecology
Polycystic Ovarian Syndrome Heidi Hallonquist, MD Concord Hospital Concord Obstetrics and Gynecology Outline Definition Symptoms Causal factors Diagnosis Complications Treatment Why are we talking about
More informationRisk of Developing Polycystic Ovarian Syndrome- Adolescent Girls
Open Access Journal Research Article DOI: 1.98/ijirms/vol-i/ Risk of Developing Polycystic Ovarian Syndrome- Adolescent Girls Satyajit Assistant Professor, Shri Guru Ram Dass College of Nursing, Hoshiarpur
More informationPolycystic Ovary Syndrome
Polycystic Ovary Syndrome What is Polycystic Ovarian Syndrome? Polycystic Ovarian Syndrome (PCOS) is characterized by the presence of multiple ovarian cysts and excess androgen production. Clinical Features
More informationAmenorrhoea: polycystic ovary syndrome
There is so much we don't know in medicine that could make a difference, and often we focus on the big things, and the little things get forgotten. To highlight some smaller but important issues, we've
More informationThe Severity of Menstrual Dysfunction as a Predictor of Insulin Resistance in PCOS
JCEM ONLINE Brief Report Endocrine Research The Severity of Menstrual Dysfunction as a Predictor of Insulin Resistance in PCOS Meredith Brower, Kathleen Brennan, Marita Pall, and Ricardo Azziz Department
More informationIntroduction. Original Article
Iran J Reprod Med Vol. 10. No. 4. pp: 307-314, July 2012 Original Article Correlation of biochemical markers and clinical signs of hyperandrogenism in women with polycystic ovary syndrome (PCOS) and women
More informationMetformin and Pioglitazone in Polycystic Ovarian Syndrome: A Comparative Study
The Journal of Obstetrics and Gynecology of India (September-October 2012) 62(5):551 556 DOI 10.1007/s13224-012-0183-3 ORIGINAL ARTICLE Metformin and Pioglitazone in Polycystic Ovarian Syndrome: A Comparative
More informationCARDIOVASCULAR EVENTS IN POLYCYSTIC OVARY SYNDROME
CARDIOVASCULAR EVENTS IN POLYCYSTIC OVARY SYNDROME Enrico Carmina Executive Director & CEO of Androgen Excess & PCOS Society Professor of Endocrinology Department of Health Sciences and Mother and Child
More informationInsulin resistance and endocrine characteristics of the different phenotypes of polycystic ovary syndrome: a prospective study
Human Reproduction, Vol.0, No.0 pp. 1 9, 2011 doi:10.1093/humrep/der418 Hum. Reprod. Advance Access published December 5, 2011 ORIGINAL ARTICLE Reproductive endocrinology Insulin resistance and endocrine
More informationPolycystic Ovary Syndrome
Polycystic Ovary Syndrome Relationship Between Androgen Levels and Blood Pressure in Young Women With Polycystic Ovary Syndrome Mei-Jou Chen, Wei-Shiung Yang, Jehn-Hsiahn Yang, Chi-Ling Chen, Hong-Nerng
More informationEffect of troglitazone on endocrine and ovulatory performance in women with insulin resistance related polycystic ovary syndrome
FERTILITY AND STERILITY VOL. 71, NO. 2, FEBRUARY 1999 Copyright 1999 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. Effect of troglitazone
More informationVitamin D Levels in Women with Polycystic Ovary Syndrome
The 6th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2016), Volume 2016 Conference Paper Vitamin D Levels in Women with Polycystic Ovary Syndrome Elida Sidabutar 1, Binarwan Halim 2,
More informationPCOS and Obesity DUB is better treated by OCPs
PCOS and Obesity DUB is better treated by OCPs Dr. Ritu Joshi Senior consultant Fortis escorts Hospital, Jaipur Chairperson Family welfare com. FOGSI (20092012) Vice President FOGSI 2014 Introduction One
More informationJMSCR Vol 05 Issue 04 Page April 2017
www.jmscr.igmpublication.org Impact Factor 5.84 Index Copernicus Value: 83.27 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v5i4.228 Study of Cutaneous Manifestations of
More informationCharacteristics of different phenotypes of polycystic ovary syndrome based on the Rotterdam criteria in a large-scale Chinese population
DOI: 10.1111/j.1471-0528.2009.02347.x www.bjog.org Fertility and assisted reproduction Characteristics of different phenotypes of polycystic ovary syndrome based on the Rotterdam criteria in a large-scale
More informationSCREENING OF POLYCYSTIC OVARIAN SYNDROME AMONG ADOLESCENT GIRLS AT CAIRO UNIVERSITY
SCREENING OF POLYCYSTIC OVARIAN SYNDROME AMONG ADOLESCENT GIRLS AT CAIRO UNIVERSITY Sahar Mansour Ibrahim, Yossria Ahmed Elsayed, Reda Esmail Reyad 4 and Hanan Fahmy Azzam 1* 2 3 1 Assistant Lecturer,
More informationPCOS IN ADOLESCENTS: EARLY DETECTION AND INTERVENTION
PCOS IN ADOLESCENTS: EARLY DETECTION AND INTERVENTION R A C H A N A S H A H, M D M S T R A S S I S TA N T P R O F E S S O R O F P E D I AT R I C S D I V I S I O N O F E N D O C R I N O L O G Y A N D D
More informationclinical outcome and hormone profiles before and after laparoscopic electroincision of the ovaries in women with polycystic ovary syndrome
& clinical outcome and hormone profiles before and after laparoscopic electroincision of the ovaries in women with polycystic ovary syndrome Zulfo Godinjak¹*, Ranka Javorić² 1 Gynecology and Obstetrics
More informationDifferentiation between polycystic ovary syndrome and polycystic ovarian morphology by means of an anti-müllerian hormone cutoff value
ORIGINAL ARTICLE Korean J Intern Med 2017;32:690-698 Differentiation between polycystic ovary syndrome and polycystic ovarian morphology by means of an anti-müllerian hormone cutoff value Do Kyeong Song,
More informationINSULIN RESISTANCE, POLYCYSTIC OVARIAN SYNDROME An Overview
INSULIN RESISTANCE, POLYCYSTIC OVARIAN SYNDROME An Overview University of PNG School of Medicine & Health Sciences Division of Basic Medical Sciences PBL MBBS III VJ Temple 1 Insulin Resistance: What is
More informationPolycystic Ovary Disease: A Common Endocrine Disorder in Women
Polycystic Ovary Disease: A Common Endocrine Disorder in Women Paul Kaplan, M.D. Clinical Professor of Reproductive Endocrinology - OHSU Courtesy Senior Research Associate, Human Physiology University
More informationPolycystic Ovary Syndrome
International Journal of Advanced Research in Biological Sciences ISSN: 2348-8069 www.ijarbs.com DOI: 10.22192/ijarbs Coden: IJARQG(USA) Volume 5, Issue 7-2018 Research Article DOI: http://dx.doi.org/10.22192/ijarbs.2018.05.07.004
More informationCREATING A PCOS TREATMENT PLAN. Ricardo Azziz, M.D., M.P.H., M.B.A. Georgia Regents University
CREATING A PCOS TREATMENT PLAN Ricardo Azziz, M.D., M.P.H., M.B.A. Georgia Regents University PCOS: CREATING A TREATMENT PLAN Good treatment plans are based on sound and complete evaluations History of
More informationROLE OF METFORMIN IN POLYCYSTIC OVARIAN SYNDROME
ORIGINAL ARTICLE ROLE OF METFORMIN IN POLYCYSTIC OVARIAN SYNDROME 1 2 3 Samdana Wahab, Farnaz, Rukhsana Karim ABSTRACT Objective: To assess the role of Metformin in Polycystic ovarian syndrome (PCOS).
More informationAFTER THE FIRST publications reporting the treatment
0021-972X/05/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 90(8):4593 4598 Printed in U.S.A. Copyright 2005 by The Endocrine Society doi: 10.1210/jc.2004-2283 Metformin and Weight Loss in
More informationA study on the clinical, biochemical and hormonal profile of polycystic ovary syndrome patients attending tertiary care hospital
International Journal of Reproduction, Contraception, Obstetrics and Gynecology Spandana JC et al. Int J Reprod Contracept Obstet Gynecol. 2017 May;6(5):1986-1992 www.ijrcog.org DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20171963
More informationValidation of a prediction model for the follicle-stimulating hormone response dose in women with polycystic ovary syndrome
Validation of a prediction model for the follicle-stimulating hormone response dose in women with polycystic ovary syndrome Madelon van Wely, Ph.D., a Bart C. J. M. Fauser, M.D., Ph.D., b Joop S. E. Laven,
More informationDiabetes and Cardiovascular Risks in the Polycystic Ovary Syndrome
Diabetes and Cardiovascular Risks in the Polycystic Ovary Syndrome John E. Nestler, M.D. William Branch Porter Professor of Medicine Chair, Department of Internal Medicine Virginia Commonwealth University
More informationPrevalence and symptomatology of polycystic ovarian syndrome in Indian women: is there a rising incidence?
International Journal of Reproduction, Contraception, Obstetrics and Gynecology Choudhary A et al. Int J Reprod Contracept Obstet Gynecol. 2017 Nov;6(11):4971-4975 www.ijrcog.org DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20175010
More informationDoppler flow velocities of uterine and ovarian arteries & hormonal patterns in patients with Polycystic Ovary Syndrome (PCOS)
Original article: Doppler flow velocities of uterine and ovarian arteries & hormonal patterns in patients with Polycystic Ovary Syndrome (PCOS) Dr. Deepali Dhingra*#, Dr. Shashi Prateek*, Dr. Renuka Sinha*,
More informationMETABOLIC SYNDROME IN REPRODUCTIVE FEMALES
METABOLIC SYNDROME IN REPRODUCTIVE FEMALES John J. Orris, D.O., M.B.A Division Head, Reproductive Endocrinology & Infertility, Main Line Health System Associate Professor, Drexel University College of
More informationPrevalence of Anovulation in Subfertile Women in Kerbala 2012, A descriptive Cross-Sectional Study
Prevalence of Anovulation in Subfertile Women in Kerbala 2012, A descriptive Cross-Sectional Study Mousa Mohsen Ali* Wasan Ghazi* HayderAamerAbboud^ *Kerbala University, College of Medicine, Gynecology
More informationClinical evaluation of hirsutism in South India
International Journal of Research in Dermatology http://www.ijord.com Original Research Article DOI: http://dx.doi.org/10.18203/issn.2455-4529.intjresdermatol20184459 Clinical evaluation of hirsutism in
More informationThoughts on PCOS Female Androgenization Syndrome FAS
Thoughts on PCOS Female Androgenization Syndrome FAS Stan Korenman, M.D. Distinguished Professor of Medicine-Endocrinology and Associate Dean - Ethics David Geffen School of Medicine at UCLA Conflicts
More informationJ Clin Endocrin Metab. First published ahead of print September 24, 2013 as doi: /jc Corrine K. Welt and Enrico Carmina
J Clin Endocrin Metab. First published ahead of print September 24, 2013 as doi:10.1210/jc.2013-2375 SPECIAL Clinical FEATURE Review Lifecycle of Polycystic Ovary Syndrome (PCOS): From In Utero to Menopause
More informationORIGINAL ARTICLE Establishing the cut off values of androgen markers in the assessment of polycystic ovarian syndrome
Malaysian J Pathol 2018; 40(1) : 33 39 ORIGINAL ARTICLE Establishing the cut off values of androgen markers in the assessment of polycystic ovarian syndrome R N Dineshinee NADARAJA MBBS, Pavai STHANESHWAR
More informationPCOS guidelines: What s relevant to general practice
PCOS guidelines: What s relevant to general Dr David Molloy Medical Director, Queensland Fertility Group International evidence based PCOS guidelines 1st ever internationally endorsed & evidence based
More informationPOLYCYSTIC OVARY SYNDROME INA S. IRABON,MD, FPOGS,FPSRM,FPSGE OBSTETRICS AND GYNECOLOGY REPRODUCTIVE ENDOCRINOLOGY AND INFERTILITY
POLYCYSTIC OVARY SYNDROME INA S. IRABON,MD, FPOGS,FPSRM,FPSGE OBSTETRICS AND GYNECOLOGY REPRODUCTIVE ENDOCRINOLOGY AND INFERTILITY TO DOWNLOAD LECTURE DECK MAIN REFERENCE Comprehensive Gynecology 7 th
More informationPolycystic Ovarian Syndrome (PCOS) LOGO
Polycystic Ovarian Syndrome (PCOS) Ma qianhong Ob/Gyn Department LOGO Contents Epidemiology and Definition Pathophysiology, Endocrinological Features Diagnostic Criteria Treatment Prognosis Introduction
More information585 International Journal of Medicine and Pharmaceutical Research
Sushma B.J Research Article IJMPR, 2014, Vol.2(2): 585-590 ISSN:2321-2624 International Journal of Medicine and Pharmaceutical Research www.pharmaresearchlibrary.com/ijmpr A Study on Association of Thyroid
More informationARTICLE. Primary Amenorrhea as a Manifestation of Polycystic Ovarian Syndrome in Adolescents
ARTICLE Primary Amenorrhea as a Manifestation of Polycystic Ovarian Syndrome in Adolescents A Unique Subgroup? Marianna Rachmiel, MD; Sari Kives, MD; Eshetu Atenafu, MSc; Jill Hamilton, MD, MSc Objective:
More informationMetabolic changes in menopausal transition
Metabolic changes in menopausal transition Terhi T. Piltonen M.D., Associate Professor Consultant, Clinical Researcher for the Finnish Medical Foundation Department of Obstetrics and Gynecology PEDEGO
More information